NCT01842165View on ClinicalTrials.gov

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 14, 2022

Study Completion Date

September 19, 2022

Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Interventions
DRUG

Intravenous injection of 177Lu-octreotate

Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.

Trial Locations (1)

B-1000

Jules Bordet Institute, Brussels

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER